Skip to main content
OpenTrials
Completed

NCT Number: NCT07042022

Digital Defocus Vision Training (DDVT) System Development and Application

Myopia is the first major disease affecting the visual health of young children. With the increase in the use of electronic products and the decrease in the time for outdoor exercise, the incidence of myopia is increasing year by year. Smith et al. firstly found that peripheral retinal defocus affects the course of myopia development in rhesus monkeys. Subsequent studies have shown that peripheral retinal hyperopic defocus can lead to the growth of the axial length (AL), leading to the development of myopia, while peripheral retinal myopic defocus can effectively slow down the growth of the AL, thus delaying the progression of myopia. Defocus signals can simultaneously change the thickness of the choroid, the vascular tissue behind the retina, and the pigment epithelium, and change the thickness and hardness of the sclera, inhibiting or promoting the growth of the axial length. Therefore, many methods have been designed to intervene in the development of myopia, including orthokeratology and peripheral defocusing glasses. The maintenance process of orthokeratology lens is complex and there is a risk of infection. Peripheral defocus glasses need to be worn for a long time, and the visual quality is unstable. It is still necessary to explore safer, more effective and more practical methods for myopia control. In addition, there may be some correlation between the development of myopia and the decrease of choroidal blood flow. Defocus signal may promote the increase of choroidal blood flow, which may be a way to prevent and control myopia.

Therefore, the investigators integrated the digital defocus paradigm into VR devices and developed a digital defocus vision training (DDVT) system. The purpose of this study was to investigate the effectiveness and safety of DDVT in the prevention and control of myopia in children.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–12 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen Universit, Guangzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • children aged 6 to 12 years
  • diagnosis of myopia with SER of -0.75 to -6.00 D
  • regular astigmatism, and astigmatism less than 2.50D
  • anisometropia less than 1.50 D
  • a logMAR best-corrected visual acuity (BCVA) of 0.00 or better
  • an understanding by participants and their legal guardians of the purpose of the study

Exclusion criteria

  • other myopia control therapies in the last 6 months (including but not limited to atropine and orthokeratology)
  • strabismus, amblyopia, congenital lens dislocation, congenital cataract, glaucoma, uveitis, nystagmus, keratoconus, eye neoplasms and other ocular diseases
  • systemic diseases such as nephrotic syndrome or diabetes
  • structural changes in the eyeball, a history of ocular surgery or trauma
  • other systemic diseases affecting eye health
  • participants in other clinical trials at the same time.

Treatment and study plan

Development of digital defocus vision training (DDVT)

Device

During a six-month follow-up period, participants received 10 minutes of DDVT twice a day (once in the morning, and the other in the afternoon) using a head-mounted VR display. In daily life during non-training sessions, participants were required to wear frame glasses with complete correction.

Primary outcomes

  1. the axial length (AL)

    Time frame: 1 year

    The axial length of the eye is the distance from the anterior surface of the cornea to the posterior surface of the retina. In a normal adult, it is approximately 24 mm , and its growth is closely related to myopia . AL was measured using the IOL Master (Carl Zeiss 500, Meditec, Oberkochen, Germany)

Secondary outcomes

  1. spherical equivalent refraction

    Time frame: 1 year

    Then used 0.5% tropicamide, five minutes apart, to perform three cycloplegia. The pupil is not considered fully dilated until it is larger than 6mm and/or has no light reflex. Autorefraction was measured in each eye using the Topcon KR-8800 (Topcon, Tokyo, Japan). Cycloplegic spherical equivalent refraction (SER) was defined as the spherical degree plus half of the cylindrical degree.

Other outcomes

  1. Negative relative accommodation

    Time frame: 1 year

    Negative relative accommodation (NRA) refers to the degree of relaxation of the eye's accommodation ability when the convergence is fixed. It is one of the important indicators for evaluating binocular visual function. NRA was measured using the Topcon CV-5000 (Topcon, Tokyo, Japan)

  2. Positive relative accommodation

    Time frame: 1 year

    Positive relative accommodation (PRA) refers to the ability of energy regulation to increase when the convergence remains unchanged in the binocular fixation state. It is used to evaluate the accommodative reserve capacity of patients。 PRA was measured using the Topcon CV-5000 (Topcon, Tokyo, Japan)

  3. The accommodation facility

    Time frame: 1 year

    The accommodation facility refers to the ability of the eye to adjust its state quickly as needed, which in the field of vision is expressed as ciliary muscle accommodation speed. The accommodation facility was measured using a ± 2.0 D flipper lens; IOP was measured using the Topcon CT-1 (Topcon, Tokyo, Japan).

Sponsors and collaborators

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Other

Registry information

Official study title

Development of Digital Defocus Vision Training (DDVT) System Based on Virtual Reality Technology and Its Application in Myopia Regulation

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 27, 2025
Registry last updated
Jan 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.